Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Triple inactivated vaccine for newcastle disease, infectious bronchitis and H9 subtype avian influenza

A technology for bronchitis and Newcastle disease, applied in the direction of virus antigen components, antibody medical components, antiviral agents, etc., can solve problems such as mixed infection, economic loss of poultry industry, immune failure, etc., to reduce immune stress response and reduce manpower Effect of labor cost and production cost economy

Inactive Publication Date: 2015-09-23
YANGLING LVFANG BIOLOGICAL ENG CO LTD
View PDF3 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Although the H9 subtype avian influenza is a low pathogenic avian influenza with low mortality rate, its clinical incidence is high. The main clinical manifestations are mild respiratory symptoms, reduced food intake, and egg production rate can drop from 90% to less than 20%. Even extinction, it can cause the death of about 30% of commercial broilers, and it is very easy to be mixed with Escherichia coli, which seriously affects the production performance of poultry and brings serious economic losses to the poultry industry.
[0005] At present, the prevention and control of the above three diseases mainly rely on vaccination, and there are corresponding inactivated single vaccines and combined vaccines on the market. The vaccine preparation technology caused by science is unstable, and the preventive immunity period for infectious bronchitis is short, which in turn leads to immune failure

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Triple inactivated vaccine for newcastle disease, infectious bronchitis and H9 subtype avian influenza
  • Triple inactivated vaccine for newcastle disease, infectious bronchitis and H9 subtype avian influenza
  • Triple inactivated vaccine for newcastle disease, infectious bronchitis and H9 subtype avian influenza

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033]The present invention is a triple inactivated vaccine of chicken Newcastle disease, infectious bronchitis and H9 subtype avian influenza, which contains inactivated chicken Newcastle disease virus La Sota strain, infectious bronchitis virus M41 strain and H9 subtype avian influenza virus SY strain; The SY strain of the H9 subtype avian influenza virus has a preservation number of CGMCC No.5968. In every 0.1 milliliter of chicken Newcastle disease virus La Sota strain virus liquid before inactivation, the content of said chicken Newcastle disease virus La Sota strain is ≥3×10 8.0 EID 50 ; In every 0.1 milliliter of infectious bronchitis virus M41 strain virus liquid before inactivation, the content of said infectious bronchitis virus M41 strain ≥ 3 × 10 6.0 EID 50 ; In every 0.1 milliliter of H9 subtype avian influenza virus SY strain virus liquid before inactivation, the content of the H9 subtype avian influenza virus SY strain ≥ 3 × 10 8.0 EID 50

[0034] Separatio...

Embodiment 2

[0045] The present invention is a triple inactivated vaccine of chicken Newcastle disease, infectious bronchitis and H9 subtype avian influenza, which contains inactivated chicken Newcastle disease virus La Sota strain, infectious bronchitis virus M41 strain and H9 subtype avian influenza virus SY strain; The SY strain of the H9 subtype avian influenza virus has a preservation number of CGMCC No.5968. In every 0.1 milliliter of chicken Newcastle disease virus La Sota strain virus liquid before inactivation, the content of said chicken Newcastle disease virus La Sota strain is ≥3×10 8.0 EID 50 ; In every 0.1 milliliter of infectious bronchitis virus M41 strain virus liquid before inactivation, the content of said infectious bronchitis virus M41 strain ≥ 3 × 10 6.0 EID 50 ; In every 0.1 milliliter of H9 subtype avian influenza virus SY strain virus liquid before inactivation, the content of the H9 subtype avian influenza virus SY strain ≥ 3 × 10 8.0 EID 50

[0046] The prep...

Embodiment 3

[0091] Adopt the chicken Newcastle disease prepared in embodiment 2, infectious bronchitis and H9 subtype avian influenza triple inactivated vaccine, batch number is 110301,110302,110303, and carry out inactivated vaccine minimum immune dose test by the following method:

[0092] Take 110 SPF chickens, 90 of them were inoculated with H120 live vaccine by nasal drops or eye drops at the age of 14 days. Three doses of 0.3ml were used to inoculate 3 batches of triple vaccines, 10 chickens were inoculated for each dose, and the remaining 20 SPF chickens were not immunized as controls. Blood was collected 4 weeks after inoculation of the immunized chicken triple vaccine, the serum was separated, and the ND, IB, AI HI antibodies were determined respectively. And take 3 groups of chickens immunized with 110301 batches of vaccines and 10 control chickens to carry out the challenge test of NDV Beijing strain, and each chicken is intramuscularly injected with chicken Newcastle disease v...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a triple inactivated vaccine for newcastle disease, infectious bronchitis and H9 subtype avian influenza. The triple inactivated vaccine comprises inactivated newcastle disease virus La Sota strain, infectious bronchitis virus M41 strain and H9 subtype avian influenza virus SY strain; the preservation number of the H9 subtype avian influenza virus SY strain is CGMCC No. 5968. The triple inactivated vaccine for newcastle disease, infectious bronchitis and H9 subtype avian influenza is good in immune effect, and stable and reliable in preparation technology.

Description

technical field [0001] The invention belongs to the technical field of biological products, and in particular relates to a triple inactivated vaccine of Newcastle disease, infectious bronchitis and H9 subtype avian influenza. Background technique [0002] Newcastle disease (ND), also known as Asian chicken plague or pseudo chicken plague, is an acute, febrile, septic and highly contagious infectious disease in poultry, characterized by high fever, dyspnea, diarrhea, nervous disorders, mucous membranes and pulp Membrane hemorrhage is characteristic. It has a high morbidity and mortality rate, and it is seriously harmful to the chicken industry. It is classified as a class A disease by OIE, and it is also classified as a class of animal disease in my country. [0003] Chicken infectious bronchitis (Infectious bronchitis, IB) infection can cause symptoms such as coughing, sneezing, and tracheal rales in chicks and broilers, slow growth, reduced egg production and lower egg qua...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/215A61K39/17A61K39/145A61P31/16A61P31/14
Inventor 焦铁军蔡曙初洪嵘胡江锋王运宏黄治国
Owner YANGLING LVFANG BIOLOGICAL ENG CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com